🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Neuroendocrine Carcinomas

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix NCT04723095n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: Follow-Up, Medical Chart Review Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors NCT06936735Phase 11 site📍 Shanghai Hansoh BioMedical R&D Company · Tests: HS-20108 Monotherapy An International Study on Pediatric Patients With Rare Tumors. NCT07072143n/a1 site📍 Padova Azienda Ospedaliera di Padova TIL Therapy in cSCC and MCC NCT07288073Phase 21 site📍 Boston Karam Khaddour, MD, MS · Tests: LN-145, Cyclophosphamide, Fludarabine, Interleukin-2 A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC NCT07416695Phase 12 sites📍 Beijing📍 Shanghai Shanghai Henlius Biotech · Tests: HLX3901 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors NCT07760012NA1 site📍 Beijing Peking University Third Hospital · Tests: 68Ga-SorB PET/CT Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma NCT05830058Phase 22 sites📍 Duarte📍 Irvine City of Hope Medical Center · Tests: Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Stereotactic B… Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC NCT07138716NA1 site📍 Beijing Luo Yaping · Tests: 68Ga-DOTA-CCK-FS PET/CT DLL3-Targeted PET/CT in Neuroendocrine Carcinoma NCT07458906NA1 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT A Study of Armored CAR T Cells in People With Cancer NCT07783477Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: DLL3-SAVVYZ-IL18 CAR T cell Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade NCT07661966NA1 site📍 New York Weill Medical College of Cornell University · Tests: Bright Light Therapy Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613Phase 1, Phase 210 sites📍 Los Angeles📍 Los Angeles📍 Stanford Obsidian Therapeutics, Inc. · Tests: OBX-115 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC NCT06277180NA1 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Surgery, Surgery A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma NCT06157827Phase 1, Phase 225 sites📍 Hefei📍 Hefei📍 Beijing Nanjing Leads Biolabs Co.,Ltd · Tests: LBL-024 for Injection, Etoposide Injection, Carboplatin Injection, Atezolizumab injection, Cisplatin injection Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors NCT07278479Phase 1, Phase 28 sites📍 Tampa📍 Atlanta📍 Chicago Molecular Partners AG · Tests: [212Pb]Pb-MP0712, [203Pb]Pb-MP0712 A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer NCT05963867Phase 11 site📍 Amsterdam Boehringer Ingelheim · Tests: BI 764532, [89Zr]Zr-BI 764532 Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors NCT06938880Phase 1, Phase 21 site📍 Guangzhou Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZGGS18 for Injection, ZG005 for Injection Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites📍 Iowa City📍 Boston📍 Royal Oak Novartis Pharmaceuticals · Tests: 225Ac-ETN029, 111In-ETN029 Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) NCT06141369NA1 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: individualized mRNA neoantigen vaccine (mRNA-0523-L001) A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity NCT06406465Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Belinostat, Cisplatin, Etoposide Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites📍 Scottsdale📍 Bethesda📍 Columbus Novartis Pharmaceuticals · Tests: dabrafenib, trametinib ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma NCT07038096Phase 1, Phase 21 site📍 Guanzhou Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZG006, ZG005 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962EARLY Phase 15 sites📍 Kingswood📍 Wollongong📍 Southport Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD204 ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors NCT03686124Phase 1, Phase 221 sites📍 Stanford📍 Aurora📍 Miami Immatics US, Inc. · Tests: IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetect® A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy